Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
320 Leser
Artikel bewerten:
(2)

ZetrOZ Systems to Showcase sam Wearable Ultrasound Device For NBA and College Athletic Trainers

As injuries sideline star players during National Basketball Association playoffs, the inventors of sustained acoustic medicine will present the FDA-cleared sam® device for soft tissue healing at the NBATA Sports Medicine Meeting in Chicago and the CATS Conference in Las Vegas.

TRUMBULL, CONNECTICUT / ACCESS Newswire / May 15, 2025 / The hamstring muscle injury that sidelined NBA star Steph Curry on May 6 is a reminder that the physical toll of playing basketball can sideline players at every level. The sam® wearable ultrasound unit from ZetrOZ Systems is clinically proven to accelerate recovery and healing of soft tissue injuries common in basketball.

ZetrOZ Systems, inventors of sustained acoustic medicine, will exhibit the sam® device this week for National Basketball Association and college athletic trainers at two upcoming conferences:

  • NBATA (National Basketball Athletic Trainers Association) Sports Medicine Meeting, May 15-16, 2025 at the InterContinental Chicago Magnificent Mile, Chicago. NBATA educates professional basketball trainers and provides specialized health care and critical support services to the teams and athletes of the NBA and NBA G League.

  • CATS (College Athletic Trainers Society) Conference, May 15-17, The Orleans Hotel, Las Vegas. CATS advocates for the needs of intercollegiate athletics, serving head and assistant athletic trainers at U.S. colleges and universities, who provide advanced care to student athletes.

Basketball, with its blend of power, contact, explosive movement and sudden pivots, puts unique demands on athletes. Basketball players are particularly susceptible to injuries including hamstring and quadricep strains, ankle sprains, shoulder strains and patellar tendinopathy, or "jumper's knee." The physical demands are greater during the postseason, after the 82-game season and with the stakes of every game even higher.

At the conferences, basketball trainers, sports medicine physicians and other medical professionals will see the latest research on the sam® wearable ultrasound device and see technology demonstrations at the ZetrOZ Systems booth.

"We're excited to have the opportunity to continue to educate NBA and college trainers about how they can use sam® to help their players get ready for practices and games, and get injured players back on the court," said George K. Lewis, CEO of ZetrOZ Systems and the inventor of sustained acoustic medicine. "The research is conclusive: sustained acoustic medicine restores function and helps people heal more quickly, without the need for invasive surgeries or potentially addictive painkillers."

sam® is a long duration, continuous, multi-hour, high frequency ultrasound treatment that has been proven effective in soft tissue healing in over 30 Level 1-5 clinical studies, and is the only long-duration ultrasound device cleared by the U.S. Food & Drug Administration for home use.

Sustained acoustic medicine, delivered by the sam® device, increases blood vessel diameters to boost blood flow, augmenting oxygenated hemoglobin at the site and removing cytokine enzymes and cellular waste for rapid healing and reduced pain.

sam® is widely used by athletic trainers in the NFL, NBA, NCAA, and other elite athletic conferences, and has successfully treated millions of soft-tissue injuries to date.

To learn more about the sam® ultrasound unit, please visit www.samrecover.com. For more information about ZetrOZ Systems, visit www.zetroz.com.

About ZetrOZ Systems
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of 48 patents and is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.

Contact Information

Catherine Hoblin
Media Contact
choblin@zetroz.com

.

SOURCE: ZetrOZ Systems



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/zetroz-systems-to-showcase-samr-wearable-ultrasound-device-for-nba-an-1028198

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.